剂量盲法肌球蛋白抑制治疗拟行室间隔减容术的梗阻性肥厚型心肌病患者:32周结局
VALOR-HCM试验为双盲随机安慰剂对照多中心研究,纳入112例拟行室间隔减容术的梗阻性肥厚型心肌病患者。32周时,原马伐凯泰组10.7%与原安慰剂交叉组13.5%的患者符合SRT指南标准或选择SRT,原马伐凯泰组左心室流出道压差持续降低且NYHA分级改善。
要点
- 马伐凯泰治疗32周持续降低拟行SRT患者的SRT需求或指南资格比例。
- 原马伐凯泰组静息压差降低33.0 mmHg,Valsalva压差降低43.0 mmHg。
- 交叉组接受马伐凯泰16周后压差降低幅度与原组32周时相似。
核心结论
- 在严重症状性oHCM患者中,马伐凯泰治疗32周持续降低 proceed to SRT 或仍符合指南资格的比例。
- 从安慰剂交叉至马伐凯泰治疗16周的患者观察到相似效应。
研究设计与样本
- 双盲随机安慰剂对照多中心试验,美国19个中心,2020年7月至2021年10月入组。
- 纳入112例接受最大耐受药物治疗且拟行SRT的oHCM患者,静息或激发左心室流出道压差≥50 mmHg。
- 原马伐凯泰组继续用药至32周,安慰剂组从第16周交叉至剂量盲法马伐凯泰至第32周。
- 剂量滴定基于研究者盲法超声评估的左心室流出道压差和左心室射血分数。
- 主要终点为32周时两组中 proceed to SRT 或仍符合指南资格的患者比例。
主要发现
- 112例随机患者中108例符合32周评估,原马伐凯泰组56例,安慰剂交叉组52例。
- 32周时原马伐凯泰组6/56例(10.7%)符合SRT指南标准或选择SRT,交叉组7/52例(13.5%)。
- 原马伐凯泰组静息左心室流出道压差降低-33.0 mmHg(95%CI -41.1至-24.9),Valsalva压差降低-43.0 mmHg(95%CI -52.1至-33.9)。
- 交叉组马伐凯泰治疗16周后静息压差降低-33.7 mmHg(95%CI -42.2至-25.2),Valsalva压差降低-52.9 mmHg(95%CI -63.2至-42.6)。
- 32周时原马伐凯泰组48/53例(90.6%)NYHA分级改善≥1级,交叉组治疗16周后35/50例(70%)改善≥1级。
关键数值与推荐
- 纳入标准:oHCM患者接受最大耐受药物治疗,拟行SRT,静息或激发左心室流出道压差≥50 mmHg。
- 主要终点:32周时 proceed to SRT 或仍符合SRT指南资格的患者比例。
- 原马伐凯泰组32周时10.7%符合SRT标准或选择SRT,交叉组13.5%。
- 原马伐凯泰组32周时静息压差降低33.0 mmHg,Valsalva压差降低43.0 mmHg。
临床怎么用
- 对于拟行SRT的严重症状性oHCM患者,马伐凯泰治疗可降低32周内 proceed to SRT 或仍符合指南资格的比例。
- 马伐凯泰治疗可持续降低左心室流出道压差并改善NYHA分级。
- 从安慰剂交叉至马伐凯泰治疗16周即可观察到压差降低和症状改善。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 US sites included patients with oHCM on maximal tolerated medical therapy referred for SRT with left ventricular outflow tract gradient ≥50 mm Hg at rest or provocation (enrollment, July 2020-October 2021). The group initially randomized to mavacamten continued the drug for 32 weeks, and the placebo group crossed over to dose-blinded mavacamten from week 16 to week 32. Dose titrations were based on investigator-blinded echocardiographic assessment of left ventricular outflow tract gradient and left ventricular ejection fraction. The principal end point was the proportion of patients proceeding with SRT or remaining guideline eligible at 32 weeks in both treatment groups. RESULTS: From the 112 randomized patients with oHCM, 108 (mean age, 60.3 years; 50% men; 94% in New York Heart Association class III/IV) qualified for week 32 evaluation (56 in the original mavacamten group and 52 in the placebo cross-over group). After 32 weeks, 6 of 56 patients (10.7%) in the original mavacamten group and 7 of 52 patients (13.5%) in the placebo cross-over group met SRT guideline criteria or elected to undergo SRT. After 32 weeks, a sustained reduction in resting left ventricular outflow tract gradient (-33.0 mm Hg [95% CI, -41.1 to -24.9]) and Valsalva left ventricular outflow tract gradient (-43.0 mm Hg [95% CI, -52.1 to -33.9]) was observed in the original mavacamten group. A similar reduction in resting (-33.7 mm Hg [95% CI, -42.2 to -25.2]) and Valsalva (-52.9 mm Hg [95% CI, -63.2 to -42.6]) gradients was quantified in the cross-over group after 16 weeks of mavacamten. After 32 weeks, improvement by ≥1 New York Heart Association class was observed in 48 of 53 patients (90.6%) in the original mavacamten group and 35 of 50 patients (70%) after 16 weeks in the cross-over group. CONCLUSIONS: In severely symptomatic patients with oHCM, 32 weeks of mavacamten treatment showed sustained reduction in the proportion proceeding to SRT or remaining guideline eligible, with similar effects observed in patients who crossed over from placebo after 16 weeks. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04349072.
引用
- Desai MY, Owens A, Geske JB, et al. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Circulation. 2022. PMID: 36335531. doi:10.1161/CIRCULATIONAHA.122.062534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。